91360 Pathology AI Completes New Round of Financing to Accelerate Technological Innovation and Market Expansion
Recently, 91360, a leading company in the field of pathological AI in China, announced the successful completion of a new round of financing. This round was led by Shenzhen Ivy Capital Management Co.,Ltd., with follow-on investment from Hangzhou Xiacheng District State-owned Investment Holding Group Co.,Ltd. The funds will support 91360 in promoting and implementing its comprehensive solution for AI-assisted diagnosis in cervical cytology, as well as sustaining the development of its digital pathology department solutions, remote consultation platform, and innovative business initiatives.
Since its establishment, 91360 has remained committed to a user-centric approach, dedicated to the deep integration of advanced AI-based pathological diagnosis technology with internet technologies. Through continuous innovation and independent research and development, the company has created multiple specialized pathology software products. Notably, its “Computer-Aided Analysis Software for Digital Pathology Images in Cervical Cytology” has achieved a breakthrough in the industry, securing the first Class III medical device registration certificate issued by the National Medical Products Administration (NMPA) in the field of pathological AI in China. In recognition of this achievement, it was named an “Outstanding Unit in the Unveiling of Artificial Intelligence Medical Device Innovation Tasks” by the Ministry of Industry and Information Technology and the National Medical Products Administration in August 2024.
Following the successful completion of this funding round, 91360 has relocated its headquarters to Gongshu District, Hangzhou, and established Jiu Yi San Liu Zero Medical Technology (Hangzhou) Co., Ltd. (hereinafter referred to as “91360 Hangzhou”) as a key base for future development and the primary entity for its initial public offering. The achievement of this strategic financing and relocation demonstrates the firm confidence of both the government and capital markets in 91360’s future prospects, marking a comprehensive upgrade in the company’s strategic layout, market expansion, and technological research and development.
Mr. Di Feng, Chairman of 91360, stated“We are honored to have entered into a strategic partnership with Hangzhou Xiacheng District State-owned Investment Holding Group Co.,Ltd. and Shenzhen Ivy Capital Management Co.,Ltd., which will bring more development opportunities and market space to the company. The company’s headquarters and new R&D center established in Hangzhou will serve as the core engine driving technological innovation and business expansion. Meanwhile, we will also build a new production base in Nanjing to meet the growing market demand.”
The company’s core competitiveness lies in its exceptional technological prowess and top-tier talent pool. The raised funds will be primarily allocated to product R&D, market promotion, and team building, including strengthening the Japan R&D Center based in Tokyo. This initiative not only reflects the company’s visionary approach to international expansion but also underscores its determination and capability to maintain a leading position in the global field of AI-powered pathology.
Mr. Lu Ming, Partner at Ivy Capital, stated:“We firmly believe in 91360’s innovative capabilities and market potential in the field of pathological AI. Its superior technological advantages, diversified product portfolio, and strong industry influence give us full confidence in the company’s future development. This investment not only recognizes the strength of the 91360 team but also reflects our optimism about the broad market prospects of pathological AI. We look forward to working hand in hand with 91360 to create a brilliant future together.”
A representative from Hangzhou Xiacheng District State-owned Investment Holding Group Co.,Ltd. stated:“Hangzhou Gongshu State-owned Investment Group has been committed to promoting the development and upgrading of high-tech industries in the region. As a leader in the field of pathology AI, 91360’s technical strength and market prospects align with our investment criteria. We are honored to become a key partner of 91360 and provide comprehensive support for its future growth. We believe that through joint efforts, 91360 will rapidly grow into an industry-leading enterprise, making greater contributions to China’s healthcare sector.”
91360 is fully aware that, as a leading enterprise in the field of pathological AI, every step of its development carries the expectations of the industry and social responsibilities. Therefore, 91360 will always adhere to the development concept of “Empowering Digital Pathology, Supporting Healthy China,” continuously exploring, innovating, and surpassing itself in the digitalization and intelligent transformation of pathology, contributing wisdom and strength to the innovation and development of China’s pathological AI industry.